Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CSF1R positive |
| Therapy | Cabozantinib + Pembrolizumab |
| Indication/Tumor Type | head and neck squamous cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CSF1R positive | head and neck squamous cell carcinoma | predicted - sensitive | Cabozantinib + Pembrolizumab | Phase II | Actionable | In a Phase II trial, Cometriq (Cabometyx, cabozantinib) and Keytruda (pemrolizumab) combination therapy was safe and resulted in a median progression-free survival of 12.8 mo and median overall survival (mOS) of 27.7 mo in patients with recurrent or metastatic head and neck squamous cell carcinoma, higher baseline density of CSF1R-positive cells correlated with improved OS (HR 6.87, p=0.040), with mOS not reached in high and 17.8 mo in low CSF1R-positive patients (PMID: 39167623; NCT03468218). | 39167623 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39167623) | Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis. | Full reference... |